SBRA Quote, Financials, Valuation and Earnings

New Concept Energy, Inc. has a net margin of 11.18% compared to Sabra Health Care REIT, Inc.'s net margin of -51.28%. Sabra Health Care REIT, Inc.'s return on equity of 6.38% beat New Concept Energy, Inc.'s return on equity of -1.7%.

Sabra Health Care REIT, Inc. has a consensus price target of $20.85, signalling upside risk potential of 12.44%. On the other hand New Concept Energy, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sabra Health Care REIT, Inc. has higher upside potential than New Concept Energy, Inc., analysts believe Sabra Health Care REIT, Inc. is more attractive than New Concept Energy, Inc..

Sabra Health Care REIT, Inc. has a beta of 0.677, which suggesting that the stock is 32.339% less volatile than S&P 500. In comparison New Concept Energy, Inc. has a beta of -0.032, suggesting its less volatile than the S&P 500 by 103.158%.

Sabra Health Care REIT, Inc. has a quarterly dividend of $0.30 per share corresponding to a yield of 6.47%. New Concept Energy, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sabra Health Care REIT, Inc. pays 223.55% of its earnings as a dividend. New Concept Energy, Inc. pays out -- of its earnings as a dividend.

Sabra Health Care REIT, Inc. quarterly revenues are $201.4M, which are larger than New Concept Energy, Inc. quarterly revenues of $39K. Sabra Health Care REIT, Inc.'s net income of $22.5M is higher than New Concept Energy, Inc.'s net income of -$20K. Notably, Sabra Health Care REIT, Inc.'s price-to-earnings ratio is 25.51x while New Concept Energy, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sabra Health Care REIT, Inc. is 5.97x versus 26.52x for New Concept Energy, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National Health Investors, Inc. has a net margin of 11.18% compared to Sabra Health Care REIT, Inc.'s net margin of 35.86%. Sabra Health Care REIT, Inc.'s return on equity of 6.38% beat National Health Investors, Inc.'s return on equity of 10.31%.

Sabra Health Care REIT, Inc. has a consensus price target of $20.85, signalling upside risk potential of 12.44%. On the other hand National Health Investors, Inc. has an analysts' consensus of $86.25 which suggests that it could grow by 12.61%. Given that National Health Investors, Inc. has higher upside potential than Sabra Health Care REIT, Inc., analysts believe National Health Investors, Inc. is more attractive than Sabra Health Care REIT, Inc..

Sabra Health Care REIT, Inc. has a beta of 0.677, which suggesting that the stock is 32.339% less volatile than S&P 500. In comparison National Health Investors, Inc. has a beta of 0.677, suggesting its less volatile than the S&P 500 by 32.288%.

Sabra Health Care REIT, Inc. has a quarterly dividend of $0.30 per share corresponding to a yield of 6.47%. National Health Investors, Inc. offers a yield of 4.73% to investors and pays a quarterly dividend of $0.92 per share. Sabra Health Care REIT, Inc. pays 223.55% of its earnings as a dividend. National Health Investors, Inc. pays out 115.16% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Sabra Health Care REIT, Inc. quarterly revenues are $201.4M, which are larger than National Health Investors, Inc. quarterly revenues of $90.6M. Sabra Health Care REIT, Inc.'s net income of $22.5M is lower than National Health Investors, Inc.'s net income of $32.5M. Notably, Sabra Health Care REIT, Inc.'s price-to-earnings ratio is 25.51x while National Health Investors, Inc.'s PE ratio is 24.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sabra Health Care REIT, Inc. is 5.97x versus 9.92x for National Health Investors, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pebblebrook Hotel Trust has a net margin of 11.18% compared to Sabra Health Care REIT, Inc.'s net margin of -8.12%. Sabra Health Care REIT, Inc.'s return on equity of 6.38% beat Pebblebrook Hotel Trust's return on equity of -3.47%.

Sabra Health Care REIT, Inc. has a consensus price target of $20.85, signalling upside risk potential of 12.44%. On the other hand Pebblebrook Hotel Trust has an analysts' consensus of $12.62 which suggests that it could grow by 11.64%. Given that Sabra Health Care REIT, Inc. has higher upside potential than Pebblebrook Hotel Trust, analysts believe Sabra Health Care REIT, Inc. is more attractive than Pebblebrook Hotel Trust.

Sabra Health Care REIT, Inc. has a beta of 0.677, which suggesting that the stock is 32.339% less volatile than S&P 500. In comparison Pebblebrook Hotel Trust has a beta of 1.530, suggesting its more volatile than the S&P 500 by 53.005%.

Sabra Health Care REIT, Inc. has a quarterly dividend of $0.30 per share corresponding to a yield of 6.47%. Pebblebrook Hotel Trust offers a yield of 0.35% to investors and pays a quarterly dividend of $0.01 per share. Sabra Health Care REIT, Inc. pays 223.55% of its earnings as a dividend. Pebblebrook Hotel Trust pays out 247847.62% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Sabra Health Care REIT, Inc. quarterly revenues are $201.4M, which are smaller than Pebblebrook Hotel Trust quarterly revenues of $398.7M. Sabra Health Care REIT, Inc.'s net income of $22.5M is higher than Pebblebrook Hotel Trust's net income of -$32.4M. Notably, Sabra Health Care REIT, Inc.'s price-to-earnings ratio is 25.51x while Pebblebrook Hotel Trust's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sabra Health Care REIT, Inc. is 5.97x versus 0.92x for Pebblebrook Hotel Trust. Usually stocks with elevated PS ratios are considered overvalued.

Ventas, Inc. has a net margin of 11.18% compared to Sabra Health Care REIT, Inc.'s net margin of 4.61%. Sabra Health Care REIT, Inc.'s return on equity of 6.38% beat Ventas, Inc.'s return on equity of 2.14%.

Sabra Health Care REIT, Inc. has a consensus price target of $20.85, signalling upside risk potential of 12.44%. On the other hand Ventas, Inc. has an analysts' consensus of $85.15 which suggests that it could grow by 7.64%. Given that Sabra Health Care REIT, Inc. has higher upside potential than Ventas, Inc., analysts believe Sabra Health Care REIT, Inc. is more attractive than Ventas, Inc..

Sabra Health Care REIT, Inc. has a beta of 0.677, which suggesting that the stock is 32.339% less volatile than S&P 500. In comparison Ventas, Inc. has a beta of 0.777, suggesting its less volatile than the S&P 500 by 22.343%.

Sabra Health Care REIT, Inc. has a quarterly dividend of $0.30 per share corresponding to a yield of 6.47%. Ventas, Inc. offers a yield of 2.39% to investors and pays a quarterly dividend of $0.48 per share. Sabra Health Care REIT, Inc. pays 223.55% of its earnings as a dividend. Ventas, Inc. pays out 923.55% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Sabra Health Care REIT, Inc. quarterly revenues are $201.4M, which are smaller than Ventas, Inc. quarterly revenues of $1.5B. Sabra Health Care REIT, Inc.'s net income of $22.5M is lower than Ventas, Inc.'s net income of $68.7M. Notably, Sabra Health Care REIT, Inc.'s price-to-earnings ratio is 25.51x while Ventas, Inc.'s PE ratio is 149.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sabra Health Care REIT, Inc. is 5.97x versus 6.40x for Ventas, Inc.. Usually stocks with elevated PS ratios are considered overvalued.